ProMIS Neurosciences Announces First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 12, 2025
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease
Six Month Interim Results Expected in 1H 2026
Read more at globenewswire.comNASDAQ:PMN (8/20/2025, 9:57:44 AM)
0.5306
-0.03 (-6.09%)
Find more stocks in the Stock Screener
